James Mohler, MD
An accomplished urologic oncologist and longtime senior leader at Roswell Park Cancer Institute, James Mohler, MD, received the 2017 Rodger Winn Award at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference in Orlando, Florida. Dr. Mohler is Associate Director and Senior Vice President for Translational Research, Chair of the Department of Urology, and Professor of Oncology at Roswell Park.
Named for the so-called father of the NCCN Clinical Practice Guidelines® (NCCN Guidelines®) program, the Rodger Winn Award is presented to a faculty member who embodies Dr. Winn’s enthusiasm, love of life, and dedication to the development of evidence-based guidelines tempered by expert judgment. The award recognizes service in the development of the NCCN Clinical Practice Guidelines, promotion of collegiality in NCCN activities, commitment to excellence, and dedication to multidisciplinary care.
Dr. Mohler has represented NCCN well on numerous occasions in multiple forums. He has demonstrated his leadership and dedication to the welfare of patients and the goals of NCCN.— Robert W. Carlson, MD
Since 2005, Dr. Mohler has served as Chair of the NCCN Guidelines in Oncology Panel for Prostate Cancer—a group composed of cancer experts nationwide responsible for crafting clinical guidelines to guide decision-making about the treatment and monitoring of prostate cancer. He joined Roswell Park in 2003 from UNC-Lineberger Comprehensive Cancer Center at the University of North Carolina. He also serves on the NCCN Guidelines Panel for Prostate Cancer Early Detection and the editorial board of JNCCN – Journal of the National Comprehensive Cancer Network. He has served on the NCCN Board of Directors and the NCCN Guidelines Steering Committee and is also Professor of Urology at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and Adjunct Professor of Urology at UNC-Lineberger.
“Dr. Mohler has represented NCCN well on numerous occasions in multiple forums. He has demonstrated his leadership and dedication to the welfare of patients and the goals of NCCN,” said Robert W. Carlson, MD, NCCN Chief Executive Officer. “As a Panel Chair, he persevered through many years and versions and expansions of the guidelines. Moreover, he is responsive to the NCCN staff and his oncology colleagues regarding any issues, concerns, or questions about the guidelines.” ■